EGFR and non-small cell lung carcinoma: For instance, we previously reported crosstalk between Hippo/YAP and epidermal growth factor receptor (EGFR)-mitogen-activated protein kinase (MAPK) signaling pathways in human NSCLC and found that YAP could promote erlotinib resistance in EGFR mutant NSCLC cells [43,44].